Vididencel

维地登赛

Report date: 2024/04/09 11:55:17

Base Information

Drug NameVididencel
Drug Alias NameAcute myeloid leukaemia vaccine (Mendus AB)Leukemic dendritic cell vaccine (Mendus AB)DCP-001
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsOvarian NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenNetherlandsNorway +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDcprime BvApceth Biopharma GmbH
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenNorthX Biologics ABApceth Biopharma GmbH +[4] 
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A